Bluejay Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 33

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $450M

Bluejay Therapeutics General Information

Description

Developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases. The company offers monoclonal antibody therapies for chronic hepatitis infections and a liver-targeting platform for liver disease treatment, enabling patients with viral and liver diseases to access targeted therapies and curative treatment approaches.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 255 Shoreline Drive
  • Suite 450
  • Redwood City, CA 94065
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 255 Shoreline Drive
  • Suite 450
  • Redwood City, CA 94065
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bluejay Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-Jan-2026 $450M Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 09-May-2024 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 16-Aug-2022 $41M $61M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 17-Jun-2021 $20M $20M Completed Pre-Clinical Trials
To view Bluejay Therapeutics’s complete valuation and funding history, request access »

Bluejay Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1
Series C
Series B
Series A-1 1,146,656 $0.000010 $0.3 $3.7 $3.7 1x $3.7 1.97%
Series A 5,408,768 $0.000010 $0.3 $3.7 $3.7 1x $3.7 9.29%
To view Bluejay Therapeutics’s complete cap table history, request access »

Bluejay Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases. The com
Drug Discovery
Redwood City, CA
33 As of 2026

Doylestown, PA
 

Amsterdam, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bluejay Therapeutics Competitors (39)

One of Bluejay Therapeutics’s 39 competitors is Imcare Biotech, a Venture Capital-Backed company based in Doylestown, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Imcare Biotech Venture Capital-Backed Doylestown, PA
NorthSea Therapeutics Venture Capital-Backed Amsterdam, Netherlands
Altimmune Formerly VC-backed Gaithersburg, MD
Apeptico Formerly VC-backed Vienna, Austria
Galectin Therapeutics Corporation Norcross, GA
You’re viewing 5 of 39 competitors. Get the full list »

Bluejay Therapeutics Patents

Bluejay Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136783-A1 Fatty acid synthase inhibitors and methods of use thereof Pending 19-Dec-2024
JP-2026522135-A Fusion proteins containing il-21 variants for the treatment of cancer and viral diseases Pending 03-Jul-2023
AU-2024289820-A1 Fusion proteins containing il21 muteins for treating cancer and viral diseases Pending 03-Jul-2023
AU-2024289820-A9 Fusion proteins containing il21 muteins for treating cancer and viral diseases Pending 03-Jul-2023
EP-4739344-A2 Fusion proteins containing il21 muteins for treating cancer and viral diseases Inactive 03-Jul-2023 A61K47/6813
To view Bluejay Therapeutics’s complete patent history, request access »

Bluejay Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bluejay Therapeutics Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arkin Capital Asset Manager Minority
Frazier Healthcare Partners PE/Buyout Minority
HBM Healthcare Investments Venture Capital Minority
InnoPinnacle Growth/Expansion Minority
Novo Holdings Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Bluejay Therapeutics FAQs

  • When was Bluejay Therapeutics founded?

    Bluejay Therapeutics was founded in 2019.

  • Where is Bluejay Therapeutics headquartered?

    Bluejay Therapeutics is headquartered in Redwood City, CA.

  • What is the size of Bluejay Therapeutics?

    Bluejay Therapeutics has 33 total employees.

  • What industry is Bluejay Therapeutics in?

    Bluejay Therapeutics’s primary industry is Drug Discovery.

  • Is Bluejay Therapeutics a private or public company?

    Bluejay Therapeutics is a Private company.

  • What is the current valuation of Bluejay Therapeutics?

    The current valuation of Bluejay Therapeutics is .

  • What is Bluejay Therapeutics’s current revenue?

    The current revenue for Bluejay Therapeutics is .

  • How much funding has Bluejay Therapeutics raised over time?

    Bluejay Therapeutics has raised $243M.

  • Who are Bluejay Therapeutics’s investors?

    Arkin Capital, Frazier Healthcare Partners, HBM Healthcare Investments, InnoPinnacle, and Novo Holdings are 5 of 13 investors who have invested in Bluejay Therapeutics.

  • Who are Bluejay Therapeutics’s competitors?

    Imcare Biotech, NorthSea Therapeutics, Altimmune, Apeptico, and Galectin Therapeutics are some of the 39 competitors of Bluejay Therapeutics.

  • When was Bluejay Therapeutics acquired?

    Bluejay Therapeutics was acquired on 23-Jan-2026.

  • Who acquired Bluejay Therapeutics?

    Bluejay Therapeutics was acquired by Mirum Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process